论文部分内容阅读
EnVivo制药公司近日公布了阿尔茨海默病治疗药α-7烟碱型乙酰胆碱受体激动剂EVP-6124的药动学和药效学数据。最新数据表明:本品血浆浓度与提高患者认知能力之间存在显著相关性(P=0.003)。该公司曾于2012年7月份报道了该药的Ⅱb期临床试验结果。该项为期6个月的双盲、安
EnVivo Pharmaceuticals recently published pharmacokinetic and pharmacodynamic data on the alpha-7 nicotinic acetylcholine receptor agonist EVP-6124, a therapeutic drug for Alzheimer’s disease. The latest data show: This product plasma concentration and improve the cognitive ability of patients there is a significant correlation (P = 0.003). The company reported its Phase IIb clinical trial results in July 2012. The six-month double-blind, Ann